Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Overweight at Piper Sandler

Piper Sandler upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a neutral rating to an overweight rating in a research note released on Wednesday morning, MarketBeat reports. Piper Sandler currently has $13.00 target price on the stock.

Other equities research analysts also recently issued reports about the stock. HC Wainwright initiated coverage on shares of Tvardi Therapeutics in a research report on Monday, June 8th. They issued a “buy” rating and a $9.00 price target for the company. Raymond James Financial raised Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective on the stock in a research note on Wednesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, April 10th. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday. Finally, Wall Street Zen cut shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 4th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tvardi Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $24.29.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ:TVRD opened at $5.00 on Wednesday. The company has a 50-day simple moving average of $3.08 and a 200 day simple moving average of $3.53. The company has a market capitalization of $46.90 million, a P/E ratio of -1.61 and a beta of 0.39. Tvardi Therapeutics has a 52-week low of $1.50 and a 52-week high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.08). As a group, equities analysts forecast that Tvardi Therapeutics will post -2.39 earnings per share for the current year.

Hedge Funds Weigh In On Tvardi Therapeutics

Several large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. bought a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $43,000. Headlands Technologies LLC purchased a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $80,000. New York State Common Retirement Fund bought a new stake in Tvardi Therapeutics during the second quarter worth $92,000. Finally, Squarepoint Ops LLC bought a new stake in Tvardi Therapeutics during the third quarter worth $318,000. Institutional investors own 44.66% of the company’s stock.

Trending Headlines about Tvardi Therapeutics

Here are the key news stories impacting Tvardi Therapeutics this week:

• Positive Sentiment: Tvardi said Phase 1 results for TTI-109 confirmed the drug’s prodrug design, showed improved tolerability, and demonstrated pharmacodynamic evidence of STAT3 target engagement, including meaningful reductions in disease-relevant immune cell populations. The company also said it plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal diseases, subject to additional funding. Article Title
• Positive Sentiment: Piper Sandler upgraded Tvardi Therapeutics from neutral to overweight and set a $13 price target, citing upside potential after the clinical update. Article Title
• Positive Sentiment: Raymond James also upgraded the stock from market perform to outperform with a $10 target, reinforcing investor optimism around the Phase 1 readout. Article Title
• Positive Sentiment: BTIG Research reaffirmed its buy rating and maintained a $15 price target, suggesting analysts see substantial additional upside if development momentum continues. Article Title
• Neutral Sentiment: Trading in TVRD was temporarily halted twice for a LULD pause, reflecting elevated volatility and unusually heavy trading rather than a new fundamental development. Article Title

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.